|
Bis-Benzamidine
|
DB02081 |
|
|
1-{2-[2-(2-Methoxyethoxy)Ethoxy]Ethoxy}-4-(1,1,3,3-Tetramethylbutyl)Benzene
|
DB02080 |
|
|
N,N-dimethylglycine
|
DB02083 |
|
|
Phosphoaminophosphonic acid guanylate ester
|
DB02082 |
[A non-hydrolyzable analog of GTP, in which the oxygen atom bridging the beta to the gamma phosphate is replaced by a nitrogen atom. It binds tightly to G-protein in the presence of Mg2+. The nucleotide is a potent stimulator of adenylate cyclase.] |
|
Dofequidar
|
DB14067 |
[Dofequidar is an antineoplastic agent.] |
|
BMS-754807
|
DB15399 |
[BMS-754807 is under investigation in clinical trial NCT00908024 (Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors).] |
|
Dihydrocapsiate
|
DB15398 |
[Dihydrocapsiate is under investigation in clinical trial NCT00999297 (Effect of 4-week Dihydrocapsiate Ingestion on Resting Metabolic Rate).] |
|
Dexniguldipine
|
DB14068 |
|
|
ONT-093
|
DB14069 |
[ONT-093 is an orally bioavailable inhibitor of P-glycoprotein (P-gp). In pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics.] |
|
Dexverapamil
|
DB14063 |
|
|
PF-06863135
|
DB15395 |
[PF-06863135 is under investigation in clinical trial NCT03269136 (Phase 1 Study Of PF-06863135, A BCMA- CD3 Bispecific Ab, In Relapse/ Refractory Multiple Myeloma).] |
|
gamma-Tocopherol
|
DB15394 |
[gamma-Tocopherol is under investigation in clinical trial NCT00836368 (In Vitro Basophil Responsiveness to Allergen Challenge After Gamma-tocopherol Supplementation in Allergic Asthmatics).] |
|
Emopamil
|
DB14064 |
[Prevents renal injury after warm & cold ischemia.] |
|
Lomerizine
|
DB14065 |
[Used to treat migraines.] |
|
GMA-161
|
DB15397 |
[GMA-161 is under investigation in clinical trial NCT00244257 (Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)).] |
|
PF-114
|
DB15396 |
[PF-114 is under investigation in clinical trial NCT02885766 (Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene).] |
|
Tetrandrine
|
DB14066 |
|
|
Elenbecestat
|
DB15391 |
[Elenbecestat is under investigation in clinical trial NCT02956486 (A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease).] |
|
Efizonerimod alfa
|
DB15390 |
[Efizonerimod alfa is under investigation in clinical trial NCT02221960 (A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors).] |
|
NS-398
|
DB14060 |
[NS-398 is a COX-2 inhibitor. It was developed as part of the mechanistic study of the cyclooxygenases.] |
